Risk factors for refractory patent ductus arteriosus to initial medical treatment in preterm infants

Aybüke Yazıcı; Hayriye Gözde Kanmaz Kutman; Gülsüm Kadıoğlu Şimşek; Betül Siyah Bilgin; Fuat Emre Canpolat; Şerife Suna Oğuz

Makale detayları

Risk factors for refractory patent ductus arteriosus to initial medical treatment in preterm infants

Yazarlar:

Aybüke Yazıcı | Hayriye Gözde Kanmaz Kutman | Gülsüm Kadıoğlu Şimşek | Betül Siyah Bilgin | Fuat Emre Canpolat | Şerife Suna Oğuz

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Neonatology

Dergi:

The European Research Journal Vol.11 Issue 3, pp.519-526

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001345457

pISSN:

2149-3189

Anahtar kelimeler:

Özet:

 Objectives: This study aims to identify risk factors and clinical markers for refractory patent ductus arteriosus to the initial medical treatment and determine appropriate treatment strategies. The goal is to define the newborns who will respond to treatment and to prevent patients from adverse effects of medical or surgical treatment of patent ductus arteriosus. Methods: Preterm infants with hemodynamically significant patent ductus arteriosus and whose gestational age was under 30 weeks were retrospectively evaluated. Infants who responded to the initial medical treatment paracetamol or ibuprofen were compared to those non-responders. Neonatal characteristics and comorbidities were compared between the groups. Results: Data from a total of 91 infants were analyzed. The mean gestational age was 271.9 weeks vs. 261.9 weeks P0.10, and birth weight was 1,056290 vs. 974318 g P0.61, respectively in responder and refractory groups. Success rates for patients treated with paracetamol n49 were 57.4, while for those treated with ibuprofen n42, it was 42.6 P0.47. Echocardiographic findings such as ductal size 2.480.69 vs. 2.550.66 mm P0.75, and left atriumaortic root ratio 1.730.4 vs. 1.640.25, P0.14 were also comparable. Incidence of severe intraventricular hemorrhage 22.7 vs 4.3, P0.009 and periventricular leukomalacia was significantly higher in the refractory group 53.1 vs. 22.2, P0.008. Conclusions: Combining multiple risk factors into a clinical decision-making model or algorithm could enhance the predictive accuracy of treatment response. Moreover, ongoing monitoring and tailored treatment adjustments based on individual responses and side effects are crucial for effectively managing patent ductus arteriosus in preterm infants.

 Objectives: This study aims to identify risk factors and clinical markers for refractory patent ductus arteriosus to the initial medical treatment and determine appropriate treatment strategies. The goal is to define the newborns who will respond to treatment and to prevent patients from adverse effects of medical or surgical treatment of patent ductus arteriosus. Methods: Preterm infants with hemodynamically significant patent ductus arteriosus and whose gestational age was under 30 weeks were retrospectively evaluated. Infants who responded to the initial medical treatment paracetamol or ibuprofen were compared to those non-responders. Neonatal characteristics and comorbidities were compared between the groups. Results: Data from a total of 91 infants were analyzed. The mean gestational age was 271.9 weeks vs. 261.9 weeks P0.10, and birth weight was 1,056290 vs. 974318 g P0.61, respectively in responder and refractory groups. Success rates for patients treated with paracetamol n49 were 57.4, while for those treated with ibuprofen n42, it was 42.6 P0.47. Echocardiographic findings such as ductal size 2.480.69 vs. 2.550.66 mm P0.75, and left atriumaortic root ratio 1.730.4 vs. 1.640.25, P0.14 were also comparable. Incidence of severe intraventricular hemorrhage 22.7 vs 4.3, P0.009 and periventricular leukomalacia was significantly higher in the refractory group 53.1 vs. 22.2, P0.008. Conclusions: Combining multiple risk factors into a clinical decision-making model or algorithm could enhance the predictive accuracy of treatment response. Moreover, ongoing monitoring and tailored treatment adjustments based on individual responses and side effects are crucial for effectively managing patent ductus arteriosus in preterm infants.

 Objectives: This study aims to identify risk factors and clinical markers for refractory patent ductus arteriosus to the initial medical treatment and determine appropriate treatment strategies. The goal is to define the newborns who will respond to treatment and to prevent patients from adverse effects of medical or surgical treatment of patent ductus arteriosus. Methods: Preterm infants with hemodynamically significant patent ductus arteriosus and whose gestational age was under 30 weeks were retrospectively evaluated. Infants who responded to the initial medical treatment paracetamol or ibuprofen were compared to those non-responders. Neonatal characteristics and comorbidities were compared between the groups. Results: Data from a total of 91 infants were analyzed. The mean gestational age was 271.9 weeks vs. 261.9 weeks P0.10, and birth weight was 1,056290 vs. 974318 g P0.61, respectively in responder and refractory groups. Success rates for patients treated with paracetamol n49 were 57.4, while for those treated with ibuprofen n42, it was 42.6 P0.47. Echocardiographic findings such as ductal size 2.480.69 vs. 2.550.66 mm P0.75, and left atriumaortic root ratio 1.730.4 vs. 1.640.25, P0.14 were also comparable. Incidence of severe intraventricular hemorrhage 22.7 vs 4.3, P0.009 and periventricular leukomalacia was significantly higher in the refractory group 53.1 vs. 22.2, P0.008. Conclusions: Combining multiple risk factors into a clinical decision-making model or algorithm could enhance the predictive accuracy of treatment response. Moreover, ongoing monitoring and tailored treatment adjustments based on individual responses and side effects are crucial for effectively managing patent ductus arteriosus in preterm infants.

 Objectives: This study aims to identify risk factors and clinical markers for refractory patent ductus arteriosus to the initial medical treatment and determine appropriate treatment strategies. The goal is to define the newborns who will respond to treatment and to prevent patients from adverse effects of medical or surgical treatment of patent ductus arteriosus. Methods: Preterm infants with hemodynamically significant patent ductus arteriosus and whose gestational age was under 30 weeks were retrospectively evaluated. Infants who responded to the initial medical treatment paracetamol or ibuprofen were compared to those non-responders. Neonatal characteristics and comorbidities were compared between the groups. Results: Data from a total of 91 infants were analyzed. The mean gestational age was 271.9 weeks vs. 261.9 weeks P0.10, and birth weight was 1,056290 vs. 974318 g P0.61, respectively in responder and refractory groups. Success rates for patients treated with paracetamol n49 were 57.4, while for those treated with ibuprofen n42, it was 42.6 P0.47. Echocardiographic findings such as ductal size 2.480.69 vs. 2.550.66 mm P0.75, and left atriumaortic root ratio 1.730.4 vs. 1.640.25, P0.14 were also comparable. Incidence of severe intraventricular hemorrhage 22.7 vs 4.3, P0.009 and periventricular leukomalacia was significantly higher in the refractory group 53.1 vs. 22.2, P0.008. Conclusions: Combining multiple risk factors into a clinical decision-making model or algorithm could enhance the predictive accuracy of treatment response. Moreover, ongoing monitoring and tailored treatment adjustments based on individual responses and side effects are crucial for effectively managing patent ductus arteriosus in preterm infants.

Makale detayları

Risk factors for refractory patent ductus arteriosus to initial medical treatment in preterm infants

Yazarlar:

Aybüke Yazıcı | Hayriye Gözde Kanmaz Kutman | Gülsüm Kadıoğlu Şimşek | Betül Siyah Bilgin | Fuat Emre Canpolat | Şerife Suna Oğuz

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Neonatology

Dergi:

The European Research Journal Vol.11 Issue 3, pp.519-526

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001345457

pISSN:

2149-3189

Patent ductus arteriosus

preterm infants

treatment

Sayı

Makale detayları

Risk factors for refractory patent ductus arteriosus to initial medical treatment in preterm infants

Yazarlar: Aybüke Yazıcı | Hayriye Gözde Kanmaz Kutman | Gülsüm Kadıoğlu Şimşek | Betül Siyah Bilgin | Fuat Emre Canpolat | Şerife Suna Oğuz

Yayıncı: Prusa Medical Publishing

Ana Başlıklar: Neonatology

Dergi: The European Research Journal Vol.11 Issue 3, pp.519-526

Belge Tipi: Makale

Yayın Tarihi: 4/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001345457

pISSN: 2149-3189

Patent ductus arteriosus

preterm infants

treatment

Sayı

Yazarlar:

Aybüke Yazıcı | Hayriye Gözde Kanmaz Kutman | Gülsüm Kadıoğlu Şimşek | Betül Siyah Bilgin | Fuat Emre Canpolat | Şerife Suna Oğuz

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Neonatology

Dergi:

The European Research Journal Vol.11 Issue 3, pp.519-526

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001345457

pISSN:

2149-3189